| __timestamp | Corcept Therapeutics Incorporated | HUTCHMED (China) Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 34916000 | 26684000 |
| Thursday, January 1, 2015 | 36949000 | 29829000 |
| Friday, January 1, 2016 | 45240000 | 39578000 |
| Sunday, January 1, 2017 | 62416000 | 43277000 |
| Monday, January 1, 2018 | 81289000 | 48645000 |
| Tuesday, January 1, 2019 | 100359000 | 52934000 |
| Wednesday, January 1, 2020 | 105326000 | 61349000 |
| Friday, January 1, 2021 | 122356000 | 127125000 |
| Saturday, January 1, 2022 | 152848000 | 136106000 |
| Sunday, January 1, 2023 | 184259000 | 133175999 |
Infusing magic into the data realm
In the ever-evolving pharmaceutical landscape, understanding the financial strategies of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Corcept Therapeutics Incorporated and HUTCHMED (China) Limited from 2014 to 2023. Over this period, Corcept Therapeutics has seen a remarkable increase in SG&A expenses, growing by over 400%, from approximately $35 million in 2014 to $184 million in 2023. In contrast, HUTCHMED's expenses have increased by nearly 400%, reaching $133 million in 2023. This trend highlights Corcept's aggressive expansion strategy, while HUTCHMED's steady growth reflects a more conservative approach. The data underscores the dynamic nature of the pharmaceutical industry, where strategic financial management can significantly impact a company's market position.
SG&A Efficiency Analysis: Comparing AbbVie Inc. and Corcept Therapeutics Incorporated
Cost Management Insights: SG&A Expenses for Takeda Pharmaceutical Company Limited and Corcept Therapeutics Incorporated
Operational Costs Compared: SG&A Analysis of Viatris Inc. and Corcept Therapeutics Incorporated
Comparing SG&A Expenses: Bio-Techne Corporation vs Corcept Therapeutics Incorporated Trends and Insights
Cost Management Insights: SG&A Expenses for Lantheus Holdings, Inc. and Corcept Therapeutics Incorporated
Comparing SG&A Expenses: Corcept Therapeutics Incorporated vs ACADIA Pharmaceuticals Inc. Trends and Insights
CRISPR Therapeutics AG or HUTCHMED (China) Limited: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Veracyte, Inc. and HUTCHMED (China) Limited
Operational Costs Compared: SG&A Analysis of Catalyst Pharmaceuticals, Inc. and HUTCHMED (China) Limited
HUTCHMED (China) Limited vs ImmunityBio, Inc.: SG&A Expense Trends
HUTCHMED (China) Limited or Travere Therapeutics, Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of HUTCHMED (China) Limited and Viridian Therapeutics, Inc.